Nuevocor is at the forefront of developing novel genetic medicines specifically aimed at treating genetic cardiomyopathies, which are heart conditions primarily caused by mutations in genes responsible for cardiac force transmission. Their lead program, NVC-001, targets lamin-related dilated cardiomyopathy, a severe form of the disease characterized by the enlargement of the left ventricle and reduced heart function. This condition is particularly challenging, as it has a poor prognosis and currently lacks effective treatments beyond cardiac transplantation. Nuevocor's approach focuses on addressing the underlying biomechanical defects associated with these genetic conditions, thereby offering a potential breakthrough in treatment options for affected patients.

Central to Nuevocor's innovative strategy is their PrOSIA mechanobiology platform, which provides deep insights into the biomechanical mechanisms that underlie various genetic cardiomyopathies. This platform enables the company to develop targeted therapies that address the root causes of these diseases, rather than relying on traditional gene replacement methods that are often ineffective for the majority of mutations involved. By leveraging this mechanobiology-centered approach, Nuevocor aims to pioneer a new generation of genetic medicines that can effectively treat multiple genetic cardiomyopathies through a pathway-specific methodology, positioning themselves as leaders in the field of genetic medicine.

Singapore

Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery

Nuevocor

Company Details